Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 10/20 | 0.57 |
| ▸ | MAPK8 | P45983 | 9/20 | 0.44 |
| ▸ | MET | P08581 | 1/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.41 |
| ▸ | RPS6KA4 | O75676 | 2/20 | 0.40 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.40 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.40 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.40 |
| ▸ | NLK | Q9UBE8 | 2/20 | 0.40 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.40 |
| ▸ | GAK | O14976 | 1/20 | 0.39 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.39 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.39 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.39 |
| ▸ | COQ8A | Q8NI60 | 1/20 | 0.39 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29537119 | 1.00 | MAPK14 (0.57) | MAPK14MAPK8METTRPA1RPS6KA4 | |
| SCHEMBL29537130 | 0.85 | BRD4 (0.45) | MAPK14MET | |
| SCHEMBL25228119 | 0.85 | BRD4 (0.45) | MAPK14MET | |
| SCHEMBL30640268 | 0.84 | MAPK14 (0.41) | MAPK14METMAPK1 | |
| SCHEMBL22139066 | 0.82 | MAPK14 (0.60) | MAPK14MAPK8TRPA1RPS6KA4MAPK9 | |
| SCHEMBL29593402 | 0.82 | MAPK14 (0.52) | MAPK14MAPK8MAPK1 | |
| SCHEMBL14266291 | 0.81 | MAPK14 (0.56) | MAPK14MAPK8TRPA1MAPK9MAPK10 | |
| SCHEMBL6073545 | 0.77 | HPGD (0.40) | MAPK14MAPK1 | |
| SCHEMBL14014098 | 0.76 | MAPK14 (0.70) | MAPK14MAPK8RPS6KA4MAPK9RPS6KA3 | |
| SCHEMBL29830087 | 0.76 | MAPK14 (0.70) | MAPK14MAPK8RPS6KA4MAPK9RPS6KA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11945816-B2 | Inhibitors of EGFR and/or HER2 and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-04-02 | — | — | US | disclosed |
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORP (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORP (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORP (US) | 2023-09-28 | — | — | US | disclosed |
| EP-4192582-A1 | KINASE INHIBITORS AND USES THEREOF | ABM Therapeutics Corporation (US) | 2023-06-14 | — | — | EP | disclosed |
| US-20220106310-A1 | INHIBITORS OF EGFR AND/OR HER2 AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. | 2022-04-07 | — | — | US | disclosed |
| US-11186574-B2 | Inhibitors of EGFR and/or HER2 and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-11186574-B2 | Inhibitors of EGFR and/or HER2 and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-20200199121-A1 | INHIBITORS OF EGFR AND/OR HER2 AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. | 2020-06-25 | — | — | US | disclosed |
| US-20200199121-A1 | INHIBITORS OF EGFR AND/OR HER2 AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. | 2020-06-25 | — | — | US | disclosed |
| US-7750016-B2 | Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones | ROCHE PALO ALTO LLC (US) | 2010-07-06 | — | — | US | disclosed |
| US-7750016-B2 | Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones | ROCHE PALO ALTO LLC (US) | 2010-07-06 | — | — | US | disclosed |
| US-20080119497-A1 | Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones | ROCHE PALO ALTO LLC | 2008-05-22 | — | — | US | disclosed |
| US-20080119497-A1 | Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones | ROCHE PALO ALTO LLC | 2008-05-22 | — | — | US | disclosed |
| US-7348331-B2 | Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones | ROCHE PALO ALTO LLC (US) | 2008-03-25 | — | — | US | disclosed |
| US-7348331-B2 | Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones | ROCHE PALO ALTO LLC (US) | 2008-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ERBB2, ERBB3, ERBB4 | MAPK14 174/4885MAPK8 124/4885MET 49/4885 |
| US-20080119497-A1 | Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones | MAPK1, MAPK7, MAPK6 | MAPK14 39/4885MAPK8 7/4885MET 3167/4885 |
| US-20220106310-A1 | INHIBITORS OF EGFR AND/OR HER2 AND METHODS OF USE | EGFR, ERBB2, ERBB3 | MAPK14 219/4885MAPK8 231/4885MET 5/4885 |
| US-11186574-B2 | Inhibitors of EGFR and/or HER2 and methods of use | EGFR, ERBB2, ERBB3 | MAPK14 219/4885MAPK8 231/4885MET 5/4885 |
| US-11945816-B2 | Inhibitors of EGFR and/or HER2 and methods of use | EGFR, ERBB2, ERBB3 | MAPK14 219/4885MAPK8 231/4885MET 5/4885 |
| US-20200199121-A1 | INHIBITORS OF EGFR AND/OR HER2 AND METHODS OF USE | EGFR, ERBB2, ERBB3 | MAPK14 219/4885MAPK8 231/4885MET 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.